Related references
Note: Only part of the references are listed.First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
Mingming Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
A Chain of Events: Regulating Target Proteins by SUMO Polymers
Nicolette S. Jansen et al.
TRENDS IN BIOCHEMICAL SCIENCES (2021)
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Solution Conformations Shed Light on PROTAC Cell Permeability
Yoseph Atilaw et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S. Dragovich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S. Dragovich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Mutant-selective degradation by BRAF-targeting PROTACs
Shanique Alabi et al.
NATURE COMMUNICATIONS (2021)
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
Kusal T. G. Samarasinghe et al.
CELL CHEMICAL BIOLOGY (2021)
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Tasuku Ishida et al.
SLAS DISCOVERY (2021)
Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow et al.
CHEMMEDCHEM (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Structure-Based Design of a Macrocyclic PROTAC
Andrea Testa et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Peter S. Dragovich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
Hao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, Synthesis, and Biological Evaluation of MEK PROTACs
Stefan Vollmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
Meng Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Optical Control of Small Molecule-Induced Protein Degradation
Yuta Naro et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Light-induced control of protein destruction by opto-PROTAC
Jing Liu et al.
SCIENCE ADVANCES (2020)
PHOTACs enable optical control of protein degradation
Martin Reynders et al.
SCIENCE ADVANCES (2020)
Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maria Maneiro et al.
ACS CHEMICAL BIOLOGY (2020)
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Xin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Khai M. Nguyen et al.
SEMINARS IN CANCER BIOLOGY (2020)
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
Yu-Hui Jin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Liam Baird et al.
MOLECULAR AND CELLULAR BIOLOGY (2020)
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex
Mary E. Matyskiela et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
Andy Pike et al.
DRUG DISCOVERY TODAY (2020)
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
Xin Lin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression
Ming Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Examining Targeted Protein Degradation from Physiological and Analytical Perspectives: Enabling Translation between Cells and Subjects
Natalie A. Daurio et al.
ACS CHEMICAL BIOLOGY (2020)
Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
Victoria G. Klein et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands
Bomie Han
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
Laura Goracci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Hirotake Furihata et al.
NATURE COMMUNICATIONS (2020)
Bardoxolone conjugation enables targeted protein degradation of BRD4
Bingqi Tong et al.
SCIENTIFIC REPORTS (2020)
Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
Akshay D. Takwale et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling
Inchul You et al.
CELL CHEMICAL BIOLOGY (2020)
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2020)
A caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Cyrille S. Kounde et al.
CHEMICAL COMMUNICATIONS (2020)
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Alina Mares et al.
COMMUNICATIONS BIOLOGY (2020)
Protein degradation through covalent inhibitor-based PROTACs
Gang Xue et al.
CHEMICAL COMMUNICATIONS (2020)
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Christian Steinebach et al.
CHEMICAL SCIENCE (2020)
Covalent Inhibition in Drug Discovery
Avick Kumar Ghosh et al.
CHEMMEDCHEM (2019)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
Carl C. Ward et al.
ACS CHEMICAL BIOLOGY (2019)
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Identification of New Small Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation
Lijie Peng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
M. Catarina Silva et al.
ELIFE (2019)
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
George M. Burslem et al.
CANCER RESEARCH (2019)
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Jessica N. Spradlin et al.
NATURE CHEMICAL BIOLOGY (2019)
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby et al.
NATURE CHEMICAL BIOLOGY (2019)
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Xiaoyu Zhang et al.
NATURE CHEMICAL BIOLOGY (2019)
RNF4-A Paradigm for SUMOylation-Mediated Ubiquitination
Ramesh Kumar et al.
PROTEOMICS (2019)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
Ashiq Masood et al.
SEMINARS IN ONCOLOGY (2019)
Enzymatic Logic of Ubiquitin Chain Assembly
Kirandeep K. Deol et al.
FRONTIERS IN PHYSIOLOGY (2019)
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Patrick Pfaff et al.
ACS CENTRAL SCIENCE (2019)
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Jieli Wei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Light-Induced Protein Degradation with Photocaged PROTACs
Gang Xue et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
Xinlin Du et al.
STRUCTURE (2019)
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dennis Dobrovolsky et al.
BLOOD (2019)
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines et al.
CANCER RESEARCH (2019)
Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
Vittoria Zoppi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Therapeutic targeting of the NRF2 and KEAP 1 partnership in chronic diseases
Antonio Cuadrado et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Blake E. Smith et al.
NATURE COMMUNICATIONS (2019)
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding
Christopher P. Tinworth et al.
ACS CHEMICAL BIOLOGY (2019)
SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
Michael J. Roy et al.
ACS CHEMICAL BIOLOGY (2019)
Targeting transcription factors in cancer - from undruggable to reality
John H. Bushweller
NATURE REVIEWS CANCER (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
Andrew P. Crew et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
Kwok-Ho Chan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Targeted protein degradation and the enzymology of degraders
Stewart L. Fisher et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2018)
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Mengchen Lu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Kristin M. Riching et al.
ACS CHEMICAL BIOLOGY (2018)
RIP kinases as modulators of inflammation and immunity
Sudan He et al.
NATURE IMMUNOLOGY (2018)
Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
George M. Burslem et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Philipp M. Cromm et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
Chemoproteomic profiling and discovery of protein electrophiles in human cells
Megan L. Matthews et al.
NATURE CHEMISTRY (2017)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
Nobumichi Ohoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
Emma D. Deeks
DRUGS (2017)
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
Ashton C. Lai et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Proteome-wide covalent ligand discovery in native biological systems
Keriann M. Backus et al.
NATURE (2016)
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Georg Petzold et al.
NATURE (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions
Weijia Cai et al.
CELL DIVISION (2016)
Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition
Julianty Frost et al.
NATURE COMMUNICATIONS (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of Halo Tag Fusion Proteins
Dennis L. Buckley et al.
ACS CHEMICAL BIOLOGY (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
The Aryl Hydrocarbon Receptor: Multitasking in the Immune System
Brigitta Stockinger et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system
Ingo Amm et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
Carles Galdeano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
Petr Klan et al.
CHEMICAL REVIEWS (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface
Inge Van Molle et al.
CHEMISTRY & BIOLOGY (2012)
Going further than Lipinski's rule in drug design
W. Patrick Walters
EXPERT OPINION ON DRUG DISCOVERY (2012)
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
Dennis L. Buckley et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Role of the Arylhydrocarbon Receptor in Lung Disease
Takahito Chiba et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2011)
Quantitative reactivity profiling predicts functional cysteines in proteomes
Eranthie Weerapana et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The arylhydrocarbon receptor repressor (AhRR): structure, expression, and function
Thomas Haarmann-Stemmann et al.
BIOLOGICAL CHEMISTRY (2006)
Chemical genetic control of protein levels: Selective in vivo targeted degradation
JS Schneekloth et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Development of protacs to target cancer-promoting proteins for ubiquitination and degradation
KM Sakamoto et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Transcription factors as targets for cancer therapy
JE Darnell
NATURE REVIEWS CANCER (2002)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
